Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab versus ustekinumab in adults with moderate to severe Crohn's disease after anti-TNF failure
2022-501645-70-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 30
01
Overview
Phase 3, randomised, single-blind trial in Crohn's disease comparing Risankizumab arm with Ustekinumab arm (2 arms). Primary endpoints: Clinical remission at Week 24, Endoscopic remission at Week 48 and 1 more. Planned start Nov 2020; status: authorised.
02
Drugs
risankizumabustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2022-501645-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501645-70-00.